Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study

Auteurs

M. Higgins, G. Curigliano, V. Dieras, S. Kuemmel, G. Kunz, P. A. Fasching, M. Campone, T. Bachelot, P. Krivorotko, S. Chan, A. Ferro, L. Schwartzberg, M. Gillet, P. M. De Sousa Alves, V. Wascotte, F. F. Lehmann, P. Goss